Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Globus Medical, Inc. reported sharply higher quarterly results for the three months ended March 31, 2026. Net sales rose to $759.9 million from $598.1 million a year earlier, while net income increased to $124.3 million from $75.5 million. Diluted earnings per share improved to $0.90 from $0.54.
Growth came from both U.S. and international markets and reflects the integration of the 2025 Nevro acquisition, which contributed $82.7 million in revenue. The company generated $202.4 million in cash from operating activities, maintained a strong cash and investments position, and recorded ongoing restructuring and acquisition-related costs while continuing to invest in R&D and enabling technologies.
Globus Medical delivered a strong start to 2026, with first quarter worldwide net sales of $759.9 million, up 27.0% year over year, or 25.5% on a constant currency basis. Base business net sales excluding Nevro were $677.2 million, up 13.2%.
GAAP net income rose to $124.3 million, an increase of 64.7%, while GAAP diluted EPS climbed to $0.90. Non-GAAP diluted EPS was $1.12, up 64.7%. Net sales from the Nevro acquisition contributed $82.7 million in the quarter.
The company reaffirmed its 2026 revenue outlook of $3.18 billion to $3.22 billion and raised its full-year non-GAAP diluted EPS guidance to $4.70–$4.80 from $4.40–$4.50, reflecting margin expansion and expected benefits from operating leverage and acquisition synergies.
Vanguard Capital Management reports beneficial ownership of 5,885,560 shares of Globus Medical Inc. common stock, representing 5.22% of the class. The filing shows sole voting power for 852,828 shares and sole dispositive power for 5,885,560 shares.
Globus Medical, Inc. will hold its 2026 annual stockholder meeting on June 3, 2026 at its Pennsylvania headquarters. Stockholders will vote to elect two Class II directors, amend the 2021 Equity Incentive Plan to add 1,000,000 Class A shares, ratify Deloitte & Touche LLP as auditor, and approve executive pay on an advisory basis.
Holders of Class A and Class B common stock as of April 13, 2026 may vote in person or by Internet, phone, or mail. The company describes how broker non-votes, abstentions, and its NYSE "controlled company" status affect governance and voting outcomes.
Globus Medical Inc: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0% beneficial ownership as disclosed in the filing. The amendment notes an internal realignment of The Vanguard Group and separate reporting by subsidiaries January 12, 2026.
Globus Medical, Inc. reported that Board member John A. DeFord, Ph.D. resigned from the Board of Directors effective immediately on March 23, 2026. The company stated that his decision was not due to any disagreement with the company.
In a related press release, Globus Medical noted that Dr. DeFord will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026, and highlighted his contributions, including work during the merger with NuVasive and service on the Nominating and Governance Committee.
Globus Medical EVP and General Counsel Kelly Huller reported option exercises and a share sale involving Class A common stock. On February 25, 2026, Huller exercised stock options for 20,000 shares granted on January 22, 2019, which are described as fully vested.
The option exercise was reported at a price of $43.58 per share, resulting in direct ownership of 20,000 shares of Class A common stock. That same day, Huller sold 20,000 shares of Class A common stock at $94.50 per share, leaving no shares reported as directly owned after the sale.
The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated November 12, 2025, indicating the sale was pre‑scheduled rather than newly decided at the time of the transaction.
GMED submitted a notice of proposed sale for 20,000 common shares via a cashless stock option exercise dated 02/25/2026. The filing lists shares outstanding 135,253,051 as of 02/25/2026. It also discloses prior sales by Kelly Huller: 10,000 shares on 02/12/2026 for $876,000 and 7,500 shares on 11/25/2025 for $674,619.
Globus Medical, Inc. files its annual report describing a fast-growing musculoskeletal and enabling-technologies business built around spine, orthopedics, biologics, neuromodulation and surgical robotics. The company reported 9 new product launches in 2025 and operates in 65 countries, with international sales representing about 19.4% of 2025 revenue.
Globus highlights two major recent deals: the 2023 stock-for-stock NuVasive merger, which broadened its spine and enabling technologies portfolio, and the 2025 Nevro acquisition, adding the HFX spinal cord stimulation platform for chronic pain in an all-cash transaction at $5.85 per Nevro share. As of February 20, 2026, Class A common shares outstanding totaled 135,253,051.
The report outlines extensive product families in Musculoskeletal Solutions and Enabling Technologies, including ExcelsiusGPS robotics and the expanding Excelsius ecosystem. It also discloses an open July 2024 FDA warning letter tied to complaint-handling and medical device reporting procedures for the ExcelsiusGPS robotic system, though the letter noted no safety concerns or manufacturing issues.